India-Italy Joint Declaration
Post of the Week
Dr. Reddy’s Laboratories Announces Launch of Oral Semaglutide Biosimilar ‘Obeda®’ (tablets) in India
Bengaluru – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), a global pharmaceutical company, today announced the launch of its oral semaglutide biosimilar, indicated for type 2 diabetes mellitus. Dr. Reddy’s oral semaglutide is available in tablet form under the brand […]
